The European Medicines Agency is seeking a positive opinion on ruxolitinib cream, with final approval resting with the executive branch.
2 reports, 2 independent
Updated Jul 1
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The European Medicines Agency is seeking a positive opinion on ruxolitinib cream, with final approval resting with the executive branch.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
European Medicines Agency
highest regulatory authority on medicines in the European Union
-
Incyte
American pharmaceutical company
-
European Commission
executive branch of the European Union
-
European Medicines Agency
highest regulatory authority on medicines in the European Union
Related events
- FDA review extended for ruxolitinib cream, while Incyte benefits from potential Trump-era tariffs, leading to analyst upgrades and recommendations.
- AbbVie submitted an application for risankizumab approval to the European Medicines Agency.
- Both the FDA and the European Medicines Agency govern drug approval processes.
- Oncopeptides AB's drug received a positive opinion from the EMA, leading to the European Commission making a final decision for the EU market.
- Innate Pharma S.A. is seeking market access for its drug lacutamab in Europe, successfully achieving Breakthrough and Fast Track designations. Sobi holds the exclusive global commercialization rights.